ACE-031 is intended for research purpose only. ACE-031 should not be used for human consumption, diagnostic, therapeutic procedures, agricultural and veterinary purposes.
ACE-031 is a soluble fusion protein that has been shown to increase muscle mass and strength in research studies. ACE-031 is being studied as a treatment for metabolic diseases, renal neoplasms of childhood, cardiovascular anomalies, age-related muscle loss, and cancer treatment related muscle loss and neuromuscular diseases. ACE-031 is a biologic therapeutic, based on activin receptor type IIB (ActRIIB). The molecule inhibits signaling via the ActRIIB receptor binding and increase muscle mass and strength. ACE-031 is a recombinant fusion protein that is artificially synthesized by fusion of standard antibody and a portion of ActRIIB receptor. The recombinant fusion protein eliminates myostatin and other biomolecules that limit muscle strength or growth.
ACE-031 belongs to class of proteins of TGF-beta super family that regulate muscle growth. ACE-031 acts on the molecular switches of these molecules and promote muscle growth. In experimental studies, ACE-031 promotes muscle growth and inhibits ActRIIB receptor signaling. In pre-clinical studies, administration of ACE-031 for two weeks increased skeletal muscle density, decreased leptin levels, and increased adiponectin.
Some bodybuilders use ACE-031 to promote muscle growth and to improve lean muscle. No serious adverse events were reported after ACE-031. Most of the common adverse events are mild and tolerable. The polypeptide contains 368 amino acid molecules, which forms a very large polypeptide complex. Muscle growth is regulated by the production of amino acids , and TGF beta protein super family is mainly the regulator as indicated earlier the on and off switch mechanism is essential for muscle production. When ActRIIB receptors interact with the GDF-8, it sends an on signal, which in turn promotes muscle growth.